McManus M E, Felton J S, Knize M G, Burgess W M, Roberts-Thomson S, Pond S M, Stupans I, Veronese M E
Department of Clinical Pharmacology, School of Medicine, Flinders University of South Australia, Bedford Park.
Carcinogenesis. 1989 Feb;10(2):357-63. doi: 10.1093/carcin/10.2.357.
The specificity of rabbit cytochrome P-450 involved in the mutagenic activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) was assessed using control and induced rabbit liver and lung microsomes, and six purified forms of cytochrome P-450. The number of revertants produced/2.5 micrograms PhIP by control rabbit liver was 260 +/- 196/10 micrograms of microsomal protein (mean +/- SD; n = 3), and this increased to 1265 +/- 248 when 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced liver microsomes were used as the activation source in the Ames test. Microsomes form phenobarbital-, rifampicin- and acetone-pretreated rabbits showed no increase in activity over controls. Control lung microsomes did not activate PhIP to a mutagen, whereas TCDD-induced lung microsomes produced 1443 +/- 136 (mean +/- SD; n = 4) Ames/Salmonella revertants/100 micrograms protein. In reconstitution experiments cytochrome P450 forms 4 and 6 were found to be efficient activators of PhIP to a mutagen Form 6 was 3.1-fold more active than form 4 and produced 4577 revertants/10 pmol with a 20-min preincubation step in the Ames test. Cytochrome form 5 produced 17 revertants/10 pmol and forms 2, 3b and 3c were not active in metabolizing PhIP to a mutagen. A highly significant statistical correlation existed between the capacity of control and induced liver microsomes to activate PhIP to a mutagen and their cytochrome P-450 form 4 (r = 0.97, r2 = 0.94) and form 6 (r = 0.95, r2 = 0.90) content. These data strongly support the involvement of polycyclic hydrocarbon-inducible forms of cytochrome P450 in the activation of PhIP in the rabbit. Anti-rabbit forms 4 and 6 IgGs recognized proteins in seven human liver microsomes of comparable mol. wt to rabbit cytochrome P-450 forms 4 and 6. However, no correlation existed between the content of these proteins and the capacity of human liver microsomes to activate PhIP.
利用对照和诱导的兔肝及肺微粒体,以及六种纯化的细胞色素P-450形式,评估了参与2-氨基-1-甲基-6-苯基咪唑并[4,5-b]吡啶(PhIP)诱变活化的兔细胞色素P-450的特异性。对照兔肝每2.5微克PhIP产生的回复突变体数为260±196/10微克微粒体蛋白(平均值±标准差;n = 3),当在艾姆斯试验中使用2,3,7,8-四氯二苯并对二恶英(TCDD)诱导的肝微粒体作为活化源时,该数值增加到1265±248。来自苯巴比妥、利福平及丙酮预处理兔的微粒体,其活性相较于对照未增加。对照肺微粒体未将PhIP活化为诱变剂,而TCDD诱导的肺微粒体产生1443±136(平均值±标准差;n = 4)个艾姆斯/沙门氏菌回复突变体/100微克蛋白。在重组实验中,发现细胞色素P450形式4和6是PhIP活化为诱变剂的有效活化剂。在艾姆斯试验中,形式6的活性比形式4高3.1倍,预孵育20分钟步骤下每10皮摩尔产生4577个回复突变体。细胞色素形式5每10皮摩尔产生17个回复突变体,形式2、3b和3c在将PhIP代谢为诱变剂方面无活性。对照和诱导的肝微粒体将PhIP活化为诱变剂的能力与其细胞色素P-450形式4(r = 0.97,r2 = 0.94)和形式6(r = 0.95,r2 = 0.90)的含量之间存在高度显著的统计相关性。这些数据有力地支持了多环芳烃诱导型细胞色素P450参与兔体内PhIP的活化。抗兔形式4和6的IgG识别了七种人肝微粒体中与兔细胞色素P-450形式4和6分子量相当的蛋白质。然而,这些蛋白质的含量与人肝微粒体活化PhIP的能力之间不存在相关性。